AzTrials
AzTrials

BronchoscopyPhase 4NCT00839371

Bronchoscopy and Bispectral Index (BIS) - Guided Sedation

A Phase 4 study testing Propofol and Midazolam in people with Bronchoscopy, run by University Hospital, Geneva at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Bronchoscopy is performed on a daily basis for diagnostic and therapeutic purposes. This procedure may cause anxiety and discomfort requiring the use of sedative drugs. In this study the investigators titrate the administration of sedatives using bispectral analysis of the EEG. Read more about this study

Who is it for?
Ages 18 to 79 yearsHealthy volunteers can take part
Conditions the study is for
Bronchoscopy
What is being tested?
Propofol and Midazolam
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
84 participants
Where
1 siteSwitzerland
Study dates
Jan 2005to Dec 2007
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 79 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • patients scheduled for bronchoscopy
  • ASA I to III
  • age between 18 and 79 years
  • capacity of discernment

Who cannot join

  • visual and psychological problems that might interfere with psychometric testing
  • chronic obstructive pulmonary disease with FEV1 < 50% predicted
  • need for an airway intubation or laryngeal mask insertion
  • fever or other signs of systemic infection
  • hemodynamic instability defined as a resting heart rate (HR) < 60 or ≥ 120 and/or a systolic blood pressure (BP) < 100 or > 180 mmHg
  • significant liver disease and documented soy allergy

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Centre Valaisan de Pneumologie

    Montana, CH-3960

Other trials in Switzerland

About this study

Official title: Bronchoscopy Under Titrated Sedation With Propofol or Midazolam: a Randomized Trial.

Bronchoscopy is performed on a daily basis for diagnostic and therapeutic purposes. This procedure may cause anxiety and discomfort requiring the use of sedative drugs.

In this study the investigators titrate the administration of sedatives using bispectral analysis of the EEG. The investigators compared 2 drugs, propofol versus midazolam regarding patient subjective tolerance, recovery of brain function, safety and operator's satisfaction.

Read the detailed description

Sedation using anxiolytic, hypnotic and /or analgesic drugs is currently used during flexible bronchoscopy (FB) to facilitate the diagnostic process and improve patient comfort.[The technique of sedation varies widely and depends primarily on the experience of the chest physician. FB can also be done without sedation. However, according to a recent survey, 80% of patients prefer to be sedated during FB and it is also well known that the operator has a tendency to overstate the tolerance of patients during the procedure.

The use of benzodiazepines for sedation undoubtedly enhances the perception and tolerance during FB and they are by far the most widely used drugs because of their ease of administration, their speed of action and the possibility to administer an antidote. The drawback of these sedative agents is related to a high variable individual sensitivity, which can lead to drug overdose and to severe respiratory depression requiring ventilatory assistance. In addition, their sedative and amnesic effects might persist several hours after the procedure.

Over the last decade, major advances in technology and pharmacology have resulted in better cerebral monitoring of anaesthesia with tools like electroencephalographic bispectral index and synthesis of sedative agents of short duration of action as propofol (P).

P is a lipidic emulsion used intravenously for induction and maintenance of anaesthesia. Its effect begins rapidly and ends faster than midazolam (M). The main advantage of P is therefore a faster recovery of mnesic, cognitive and motor functions, whereas M induces anterograde amnesia (1-2 h after bolus) and slower motor reaction . This gives to P a keen interest in ambulatory practice. While P is commonly and safely used in several gastroenterological endoscopic procedures, its use by pneumologist is currently hampered by a lack of expertise and could benefit from collaboration with the anaesthesia team.

This is a randomised trial comparing recovery of brain function and patient subjective tolerance following FB after administration either of P or M for sedation. Patients and operators are blinded to the sedative drug, which is administered and titrated by another chest physician.

For each procedure, the staff consists of a chest physician trained in FB (operator), a physician in charge of sedation and two nurses for technical assistance and proper data recording. Before the procedure, blood pressure (BP), heart rate (HR), oxygen saturation (SaO2) and weight are recorded. The patient is placed in supine position, fitted with a nasal oxygen cannula and a peripheral intravenous access (18-20 G) for the infusion of crystalloids. Oxygen is administered only if SaO2 was < 92%. Local anaesthesia is done using lidocaïne 10 % and 1% in the pharynx and central airways respectively. The sedative drugs syringes and lines are hidden from the operator by a sheet. Sedation is then started with P or M according to randomization for any FB as follows: We inject in both groups a 5 ml bolus of lidocaine 1% (50 mg) (prevention of pain associated with P injection), followed by either a 40 mg (4 ml) bolus of P or 2 mg of M. The re-injection of 20 mg (2ml) of P or 2 mg of M was allowed every 2 minutes to achieve and maintain BIS values between 70 and 85 and OAA/S of 3-4. Blood pressure, oxygen saturation, heart rate, BIS and OAA/S are monitored continuously and recorded every 3 minutes during the procedure and at 5, 15, 30, 45 and 60 minutes after its end. We record the time necessary to achieve the targeted BIS value after the injection of the sedative drug, the duration of FB, the electroencephalographic recovery time, defined as the time to reach a BIS value > 90 after the end of FB and total doses of M and P.

Sixty minutes and 24 hours after FB, operator and patient, both blinded to the allocation, evaluate the tolerance to the FB with visual analogic scales (VAS) (1 mm: excellent tolerance, 100 mm very low tolerance) to assess 1) the global tolerance of the procedure and 2) the intensity of 4 key symptoms during FB (pain, nausea, breathlessness and cough).

Before the procedure and 15 and 60 minutes after the procedure, patients are asked to complete CPT trials to evaluate cognitive recovery.

Conditions
Bronchoscopy
Being tested
Propofol, Midazolam
Keywords
bispectral analysis, bronchoscopy, midazolam, propofol, recovery, sedation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PropofolDrug

    i.v. propofol titration until adequate depth of sedation

  • MidazolamDrug

    i.v. midazolam titration until adequate depth of sedation

Study groups in NCT00839371
Study groupRoleWhat they receive
MidazolamActive comparatori.v. midazolam titration until adequate depth of sedation
Receives: Drug: Midazolam
PropofolActive comparatori.v. propofol titration until adequate depth of sedation
Receives: Drug: Propofol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. electroencephalographic (BIS) and functional cognitive recovery

    Measured: 24h

Secondary outcomes (2)
  1. The secondary endpoints are patient subjective tolerance, operator evaluation of patient tolerance and cardiopulmonary adverse events

    Measured: 24h

  2. respiratory depression, hypotension

    Measured: 24h

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2009 (estimated)
  2. Study startJan 2005
  3. Primary completionNov 2007
  4. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
84 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00839371
Sponsor's protocol ID
HUG-CVP 2007-1
Status last verified
Feb 2009
First submitted
6 Feb 2009
Last updated
9 Feb 2009
Results posted
No
Data monitoring committee
No

Publications

  • Clark G, Licker M, Younossian AB, Soccal PM, Frey JG, Rochat T, Diaper J, Bridevaux PO, Tschopp JM. Titrated sedation with propofol or midazolam for flexible bronchoscopy: a randomised trial. Eur Respir J. 2009 Dec;34(6):1277-83. doi: 10.1183/09031936.00142108. Epub 2009 May 14.

    PubMed 19443532

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Propofol and Midazolam in people with Bronchoscopy, run by University Hospital, Geneva at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

electroencephalographic (BIS) and functional cognitive recovery (time frame: 24h). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00839371, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in